Artigo Acesso aberto Revisado por pares

Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS

2018; BioMed Central; Volume: 6; Issue: 1 Linguagem: Inglês

10.1186/s40560-018-0321-9

ISSN

2052-0492

Autores

G. Umberto Meduri, Reed Siemieniuk, Rachel A. Ness, Samuel J. Seyler,

Tópico(s)

Sepsis Diagnosis and Treatment

Resumo

An updated meta-analysis incorporating nine randomized trials (n = 816) investigating low-to-moderate dose prolonged glucocorticoid treatment in acute respiratory distress syndrome (ARDS) show moderate-to-high quality evidence that glucocorticoid therapy is safe and reduces (i) time to endotracheal extubation, (ii) duration of hospitalization, and (iii) mortality (number to treat to save one life = 7), and increases the number of days free from (i) mechanical ventilation, (ii) intensive care unit stay, and (iii) hospitalization. Recent guideline suggests administering methylprednisolone in patients with early moderate-to-severe (1 mg/kg/day) and late persistent (2 mg/kg/day) ARDS (conditional recommendation based on moderate quality of evidence).

Referência(s)